| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03627f82d4edc6567f9627df6efdde5d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C51-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C51-487 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-487
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B57-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B55-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C227-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-56 |
| filingDate |
1993-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_505035668feb188fa82d416ffaf032ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ab46cb8be551ad351a9ee70d35049ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89093406cdbc308a8a014e5dab9604b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d320f4796556b018f33b5aea9951a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b30d2102f852346f47dcebf8902fae7 |
| publicationDate |
1994-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9412451-A1 |
| titleOfInvention |
SELECTIVE PRECIPITATION OF α-ARYL CARBOXYLIC ACID SALTS |
| abstract |
A process is provided whereby S(+)-ibuprofen or R(-)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of one of the enantiomers in the ibuprofen enantiomeric mixture. Upon precipitation of one ibuprofen enantiomer from the mixture, the overall precipitate and reaction mixture can be held for a sufficient period of time at a second temperature to allow the first precipitate to redissolve into the reaction mixture and the other ibuprofen enantiomer to precipitate out of the mixture in the salt form. Optically active ibuprofen is racemized by being heated at 100 °C to 300 °C in the substantial absence of other materials. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010012471-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2105948-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7381835-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5463117-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2149546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9952528-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6291527-B1 |
| priorityDate |
1992-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |